Drugs / GLK-321
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07400965 | Dec 2025 → Sep 2026 overdue | blepharitis | Glaukos Corporation | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-25 | Glaukos Corporation | Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis glaukos.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLK-321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07400965 ↗ |